Insulet Co. (NASDAQ:PODD – Get Rating) SVP Dan Manea sold 200 shares of the stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $294.62, for a total value of $58,924.00. Following the completion of the sale, the senior vice president now owns 3,158 shares of the company’s stock, valued at approximately $930,409.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Insulet Trading Down 1.7 %
Shares of NASDAQ PODD opened at $290.60 on Tuesday. The company has a market cap of $20.18 billion, a price-to-earnings ratio of 1,210.83 and a beta of 0.79. Insulet Co. has a 12-month low of $181.00 and a 12-month high of $320.00. The company has a current ratio of 3.98, a quick ratio of 3.00 and a debt-to-equity ratio of 3.22. The stock’s 50 day simple moving average is $254.70 and its 200 day simple moving average is $240.92.
Institutional Trading of Insulet
Several hedge funds have recently made changes to their positions in PODD. William Blair Investment Management LLC bought a new stake in shares of Insulet in the 1st quarter worth approximately $136,901,000. Clearbridge Investments LLC lifted its holdings in shares of Insulet by 38.8% in the 1st quarter. Clearbridge Investments LLC now owns 1,696,822 shares of the medical instruments supplier’s stock worth $452,016,000 after purchasing an additional 474,545 shares during the last quarter. Echo Street Capital Management LLC lifted its holdings in shares of Insulet by 60.8% in the 1st quarter. Echo Street Capital Management LLC now owns 802,434 shares of the medical instruments supplier’s stock worth $213,760,000 after purchasing an additional 303,355 shares during the last quarter. Lord Abbett & CO. LLC increased its position in Insulet by 652.1% in the 3rd quarter. Lord Abbett & CO. LLC now owns 298,819 shares of the medical instruments supplier’s stock valued at $68,549,000 after acquiring an additional 259,089 shares during the period. Finally, Renaissance Technologies LLC increased its position in Insulet by 106.9% in the 1st quarter. Renaissance Technologies LLC now owns 182,900 shares of the medical instruments supplier’s stock valued at $48,723,000 after acquiring an additional 94,500 shares during the period.
Wall Street Analysts Forecast Growth
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.
- Get a free copy of the StockNews.com research report on Insulet (PODD)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Is Ardelyx is A Buy After Slip in Early 2022
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.